A detailed history of Morgan Stanley transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Morgan Stanley holds 274,450 shares of PRQR stock, worth $732,781. This represents 0.0% of its overall portfolio holdings.

Number of Shares
274,450
Previous 77,942 252.12%
Holding current value
$732,781
Previous $129,000 286.82%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.64 - $2.24 $322,273 - $440,177
196,508 Added 252.12%
274,450 $499,000
Q2 2024

Oct 17, 2024

BUY
$1.65 - $2.39 $17,079 - $24,738
10,351 Added 15.31%
77,942 $129,000
Q2 2024

Aug 14, 2024

BUY
$1.65 - $2.39 $17,079 - $24,738
10,351 Added 15.31%
77,942 $129,000
Q1 2024

Oct 17, 2024

SELL
$1.89 - $2.85 $19,563 - $29,500
-10,351 Reduced 13.28%
67,591 $154,000
Q1 2024

Aug 16, 2024

SELL
$1.89 - $2.85 $87,166 - $131,442
-46,120 Reduced 40.56%
67,591 $154,000
Q1 2024

May 15, 2024

SELL
$1.89 - $2.85 $87,166 - $131,442
-46,120 Reduced 40.56%
67,591 $154,000
Q4 2023

Aug 16, 2024

BUY
$1.15 - $2.21 $41,134 - $79,049
35,769 Added 45.89%
113,711 $225,000
Q4 2023

Feb 13, 2024

SELL
$1.15 - $2.21 $263,634 - $506,635
-229,247 Reduced 66.84%
113,711 $225,000
Q3 2023

Nov 15, 2023

SELL
$1.3 - $1.77 $198,325 - $270,027
-152,558 Reduced 30.79%
342,958 $445,000
Q2 2023

Aug 14, 2023

SELL
$1.62 - $2.32 $248,414 - $355,753
-153,342 Reduced 23.63%
495,516 $802,000
Q1 2023

May 15, 2023

BUY
$1.99 - $3.66 $537,713 - $988,961
270,208 Added 71.36%
648,858 $1.38 Million
Q4 2022

Feb 14, 2023

SELL
$0.8 - $3.7 $79,250 - $366,533
-99,063 Reduced 20.74%
378,650 $1.4 Million
Q3 2022

Nov 14, 2022

BUY
$0.74 - $0.89 $58,399 - $70,237
78,918 Added 19.79%
477,713 $355,000
Q2 2022

Oct 27, 2022

BUY
$0.56 - $1.0 $110,258 - $196,891
196,891 Added 97.52%
398,795 $311,000
Q2 2022

Aug 15, 2022

BUY
$0.56 - $1.0 $110,258 - $196,891
196,891 Added 97.52%
398,795 $311,000
Q1 2022

Oct 27, 2022

SELL
$0.9 - $8.39 $177,201 - $1.65 Million
-196,891 Reduced 49.37%
201,904 $183,000
Q1 2022

May 13, 2022

BUY
$0.9 - $8.39 $148,754 - $1.39 Million
165,283 Added 451.33%
201,904 $183,000
Q4 2021

Feb 14, 2022

SELL
$6.58 - $8.44 $489,874 - $628,349
-74,449 Reduced 67.03%
36,621 $293,000
Q3 2021

Nov 15, 2021

BUY
$5.16 - $8.47 $573,121 - $940,762
111,070 New
111,070 $930,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $191M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.